Evenity (Romosozumab) and Bupropion Interaction

Why This Drug Pair Raises Questions

Patients with postmenopausal osteoporosis frequently carry comorbid depression, and bupropion ranks among the most commonly prescribed antidepressants in the United States. An estimated 20% of women with osteoporosis also meet criteria for major depressive disorder [1]. When a clinician prescribes romosozumab for high-fracture-risk patients who already take bupropion, the natural question is whether these drugs interact.

The short answer: they do not share a metabolic pathway. Romosozumab is a humanized monoclonal IgG2 antibody that binds sclerostin, a glycoprotein secreted by osteocytes [2]. Like all therapeutic monoclonal antibodies, romosozumab undergoes proteolytic degradation into amino acids through the reticuloendothelial system. It does not pass through hepatic Phase I or Phase II metabolism. Bupropion, by contrast, is a small-molecule aminoketone metabolized primarily by CYP2B6, with its active metabolite hydroxybupropion formed via that enzyme [3]. Bupropion also acts as a moderate inhibitor of CYP2D6. Because romosozumab never encounters CYP enzymes, bupropion's inhibitory activity on CYP2D6 (or any other isoenzyme) is pharmacokinetically irrelevant to romosozumab disposition.

Pharmacokinetic Analysis: No Shared Metabolic Pathway

Romosozumab reaches peak serum concentration (Cmax) approximately 5 days after a 210 mg subcutaneous injection, with a mean bioavailability of 81% and an estimated half-life of 12.8 days [2]. Its clearance follows target-mediated drug disposition: as sclerostin levels decrease with treatment, nonlinear clearance decreases, and trough concentrations rise over the first three monthly doses before reaching steady state.

None of these pharmacokinetic parameters involve CYP450 enzymes, P-glycoprotein (P-gp), or organic anion/cation transporters. The FDA's 2019 clinical pharmacology review for romosozumab states that "no formal drug-drug interaction studies were conducted" because "as a monoclonal antibody, romosozumab is not expected to undergo metabolism by cytochrome P450 enzymes or other drug-metabolizing enzymes" [2].

Bupropion's metabolic profile is well characterized. CYP2B6 converts bupropion to hydroxybupropion, while carbonyl reductases produce threohydrobupropion and erythrohydrobupropion [3]. Bupropion inhibits CYP2D6 with meaningful clinical consequences for CYP2D6 substrates like desipramine, whose AUC increases 5-fold when coadministered [3]. This inhibition, though potent, has zero bearing on a biologic drug that bypasses the liver entirely.

A 2020 review in Clinical Pharmacology & Therapeutics confirmed that "monoclonal antibodies do not interact with small-molecule drugs through traditional pharmacokinetic mechanisms, and formal interaction studies are generally unnecessary" [4]. The European Medicines Agency's guideline on immunogenicity assessment echoes this position [5].

Pharmacodynamic Considerations Worth Noting

While the pharmacokinetic picture is clean, two pharmacodynamic topics deserve attention in clinical practice: cardiovascular risk and bone-density effects of bupropion.

Cardiovascular Overlap

Romosozumab carries an FDA boxed warning based on the ARCH trial (N=4,093), which compared romosozumab-to-alendronate sequencing against alendronate alone in postmenopausal women with osteoporosis and a fragility fracture [6]. During the 12-month romosozumab treatment period, adjudicated major adverse cardiovascular events (MACE) occurred in 50 patients (2.5%) in the romosozumab group versus 38 (1.9%) in the alendronate group [6]. The FDA label now advises against using romosozumab in patients who have had a myocardial infarction or stroke within the preceding year [2].

Bupropion, in contrast, does not carry a cardiovascular boxed warning. Some data suggest bupropion may modestly increase blood pressure. A meta-analysis of 10 trials (N=2,338) found a mean systolic increase of 1.6 mmHg with bupropion SR compared with placebo [7]. The CONTRAVE (naltrexone-bupropion) cardiovascular outcomes trial was terminated early but showed no excess MACE signal in the interim analysis [8]. These effects are mild, but in a patient population already flagged for CV surveillance because of romosozumab, blood pressure monitoring at each monthly injection visit is sensible.

Bupropion and Bone Mineral Density

A question with less clinical certainty: does bupropion affect bone? SSRIs have a documented negative association with bone mineral density (BMD). A meta-analysis of 19 studies found SSRI use associated with a 1.7-fold increased fracture risk (OR 1.72 to 95% CI 1.44-2.07) [9]. Bupropion, as an NDRI rather than an SSRI, does not share the serotonin transporter mechanism implicated in osteoclast regulation. Preclinical rodent data suggest bupropion does not impair bone formation markers the way fluoxetine does [10].

The Women's Health Initiative observational cohort (N=9,532 antidepressant users) found that SSRI users had significantly lower hip BMD compared with non-users, but the bupropion subgroup was too small for independent analysis [11]. On balance, bupropion appears to be among the safer antidepressant choices for patients with osteoporosis, though prospective trial data specific to bupropion and fracture risk remain limited.

Dr. Felicia Cosman, professor of medicine at Columbia University and lead author of the 2020 National Osteoporosis Foundation clinician's guide, has noted: "When selecting an antidepressant for a patient on osteoporosis therapy, agents that avoid serotonin reuptake inhibition may offer a theoretical skeletal advantage, though we lack randomized evidence to mandate that preference" [12].

Seizure Threshold: A Bupropion-Specific Concern

Bupropion lowers the seizure threshold in a dose-dependent fashion. The incidence of seizure with bupropion IR at doses up to 450 mg/day is approximately 0.4% (4 per 1,000), rising sharply at doses above 450 mg/day to roughly 5 per 1,000 [3]. Romosozumab has no known effect on seizure threshold, and seizures do not appear among the adverse events in the FRAME trial (N=7,180) or ARCH trial databases [2][6].

This means the seizure consideration is bupropion-specific and unrelated to the drug combination. Clinicians should follow standard bupropion prescribing precautions: avoid use in patients with a seizure disorder or history of anorexia/bulimia, do not exceed maximum recommended doses, and counsel on alcohol restriction. The addition of romosozumab does not modify these precautions.

Immunogenicity and Injection-Site Reactions

Romosozumab-related immunogenicity data show that 18.2% of patients in clinical trials developed anti-romosozumab antibodies, with 0.7% developing neutralizing antibodies [2]. There is no biological mechanism by which bupropion, a small-molecule aminoketone, would alter antibody formation against a monoclonal antibody. Immunogenicity is driven by patient-specific immune factors, not by coadministered small molecules that lack immunomodulatory properties.

Injection-site reactions occurred in 5.2% of romosozumab patients in the FRAME trial versus 2.9% with placebo [13]. Bupropion would not be expected to modify local tissue reactions at a subcutaneous injection site. No case reports in the FDA Adverse Event Reporting System (FAERS) link bupropion coadministration to increased romosozumab injection-site events.

Monitoring Recommendations for Concomitant Use

The American Association of Clinical Endocrinology (AACE) 2020 guidelines for postmenopausal osteoporosis recommend the following during romosozumab treatment, regardless of concomitant medications [14]:

• Serum calcium, 25-hydroxyvitamin D, and phosphorus at baseline and periodically during treatment
• DXA scan at baseline and after 12 months (completion of romosozumab course)
• Clinical assessment for signs and symptoms of cardiovascular events at each injection visit

Dr. Michael McClung, founding director of the Oregon Osteoporosis Center and co-author of the FRAME trial, has stated: "Romosozumab's 12-month treatment window demands that we frontload our monitoring. Cardiovascular status should be assessed before and during treatment, especially in patients with additional risk factors" [15].

For patients concurrently on bupropion, two additions to this routine are reasonable:

1. Blood pressure check at each monthly romosozumab injection visit. This captures both the mild pressor effect of bupropion and the cardiovascular vigilance required by the romosozumab boxed warning.
2. Review of bupropion dose and adherence to confirm the patient remains within the approved dose range, given that romosozumab patients tend to be older (mean age in FRAME: 70.9 years [13]) and may have renal changes that slow bupropion metabolite clearance.

No dose adjustment to either drug is required based on coadministration alone.

When the Combination May Warrant Extra Caution

Three clinical scenarios merit closer attention, not because of a direct drug-drug interaction, but because of overlapping risk profiles in the patient population:

Prior cardiovascular event. Romosozumab is contraindicated per the boxed warning in patients with MI or stroke within the past year [2]. Bupropion does not change this contraindication, but a prescriber evaluating cardiovascular fitness for romosozumab should document the full medication list, including bupropion, in their risk-benefit assessment.

Hypocalcemia. Romosozumab can cause hypocalcemia, particularly in patients with renal impairment or inadequate calcium/vitamin D intake [2]. Bupropion does not affect calcium homeostasis, but symptoms of hypocalcemia (muscle cramps, paresthesias, irritability) can overlap with bupropion side effects (tremor, agitation), complicating clinical interpretation. Checking serum calcium at months 1, 3, and 6 of romosozumab treatment helps differentiate the cause.

Fall risk in elderly patients. Both romosozumab patients and bupropion users skew older. Bupropion's side-effect profile includes dizziness (5-11% across formulations [3]), and falls in osteoporotic patients carry high fracture consequence. An ARCH subanalysis found that 6.2% of clinical fractures during the study period followed a fall from standing height [6]. A focused fall-risk assessment, covering orthostatic vitals, home safety, and polypharmacy review, adds value in this overlap population.

Transition Therapy After Romosozumab Completion

Romosozumab is given for a fixed 12-month course, after which patients transition to an anti-resorptive agent (typically alendronate or denosumab) to maintain bone gains [14]. Bupropion continues through this transition without adjustment. The same absence of CYP-mediated interaction applies to the follow-on anti-resorptive: alendronate is not metabolized hepatically (it is excreted unchanged by the kidney [16]), and denosumab is another monoclonal antibody cleared by proteolysis [17].

Patients should be counseled that stopping romosozumab without starting a follow-on agent leads to rapid BMD loss. In the FRAME extension, patients who received placebo after romosozumab lost 60% of their lumbar-spine BMD gains within 12 months [13]. This timeline concern is independent of bupropion use but underscores the importance of treatment continuity planning at the time of romosozumab initiation.